Larson Financial Group
CRSP icon

Larson Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Larson Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$105K Buy
1,902
+469
+33% +$25.3K ﹤0.01% 1214
2026
Q2 		$78.2K Buy
1,433
+95
+7% +$5.01K ﹤0.01% 1316
2026
Q1 		$63.6K Buy
1,338
+456
+52% +$24.1K ﹤0.01% 1225
2025
Q4 		$46.3K Buy
882
+639
+263% +$38.3K ﹤0.01% 1269
2025
Q3 		$15.7K Sell
243
-67
-22% -$3.85K ﹤0.01% 1775
2025
Q2 		$15.1K Sell
310
-1
-0.3% -$39 ﹤0.01% 1622
2025
Q1 		$10.6K Sell
311
-159
-34% -$6.74K ﹤0.01% 1614
2024
Q4 		$18.5K Sell
470
-14
-3% -$661 ﹤0.01% 1248
2024
Q3 		$22.7K Sell
484
-81
-14% -$4.11K ﹤0.01% 1152
2024
Q2 		$30.5K Buy
565
+276
+96% +$16K ﹤0.01% 937
2024
Q1 		$19.7K Buy
289
+20
+7% +$1.43K ﹤0.01% 892
2023
Q4 		$16.8K Hold
269
– – ﹤0.01% 896
2023
Q3 		$12.2K Sell
269
-30
-10% -$1.55K ﹤0.01% 943
2023
Q2 		$16.8K Hold
299
– – ﹤0.01% 789
2023
Q1 		$13.5K Sell
299
-15
-5% -$729 ﹤0.01% 837
2022
Q4 		$12.8K Sell
314
-100
-24% -$5.3K ﹤0.01% 790
2022
Q3 		$27K Hold
414
– – ﹤0.01% 562
2022
Q2 		$25K Hold
414
– – ﹤0.01% 501
2022
Q1 		$26K Sell
414
-8
-2% -$502 ﹤0.01% 484
2021
Q4 		$32K Buy
422
+151
+56% +$13.2K 0.01% 460
2021
Q3 		$30K Buy
271
+167
+161% +$21K 0.01% 379
2021
Q2 		$17K Hold
104
– – ﹤0.01% 463
2021
Q1 		$13K Buy
104
+15
+17% +$2.26K ﹤0.01% 486
2020
Q4 		$14K Buy
89
+60
+207% +$7.09K ﹤0.01% 433
2020
Q3 		$2K Hold
29
– – ﹤0.01% 589
2020
Q2 		$2K Hold
29
– – ﹤0.01% 548
2020
Q1 		$1K Buy
+29
New +$1.5K ﹤0.01% 463

Other funds holding CRSP

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Larson Financial Group's CRSP Position: Q3 2026 in Review

Larson Financial Group increased its CRISPR Therapeutics (CRSP) stake by 33% in Q3 2026, buying an estimated $25.3K and bringing the position to 1,902 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Larson Financial Group first reported a position in CRSP in Q1 2020 and has held it in 27 quarters since. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Larson Financial Group held 1,902 shares of CRISPR Therapeutics worth $105K as of Q3 2026.
  • Larson Financial Group bought 469 CRISPR Therapeutics shares in Q3 2026, an estimated $25.3K.
  • CRISPR Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #1214 holding.
  • Larson Financial Group first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 27 quarters since.
  • 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.